中国临床药理学杂志2017，Vol.33Issue(16)：1523-1526,4.DOI:10.13699/j.cnki.1001-6821.2017.16.002
聚乙二醇干扰素α-2a注射液联合利巴韦林片治疗脾栓塞术后丙型病毒性肝炎肝硬化的临床研究
Clinical of of pegylated interferon α-2a injection combined with ribavarin tablets on hepatitis C virus-related cirrhosis patients after splenic embolization
摘要
Abstract
Objective To analyze the effect and safety of profile pegylated interferon α-2a (PEG-IFN-α-2a) combined with ribavarin on hepatitis C virus (HCV)-related cirrhosis patients after splenic embolization.Methods Sixty-four HCV patients who underwent splenic embolization were randomly divided into treatment group and control group (32 cases in each group).Control group was given subcutaneous injection of recombinant human interferon α-2b (rhIFN α-2b) every other day,and oral administration of ribavarin 300 mg three times a day;Treatment group did not only receive the treatment above,but also received subcutaneous injection pegylated interferon α-2a 180 μg once a week.Both groups were treated for 12 weeks.HCV RNA positive rate,blood routine parameters,serum alanine aminotransferase (ALT),aspartate aminotransferase (AST) levels,and adverse drug reactions were compared between the two groups.Results Before treatment,HCV RNA positive rate of the two groups were both 100％ (32/32 cases),after treatment,HCV RNA positive rate of treatment group was 53.13％ (17/32 cases) and that of and the control group was 78.12％ (25/32 cases),the difference was statistically significant (P ＜ 0.05).Mter treatment,the ANC of treatment group was (4.76 ± 0.33) × 109/L and that of the control group was (3.92 ±0.17) × 109/L,PLT levels of treatment group was (142.73 ± 17.04) × 109/L and that of and the control group was (128.72 ± 17.96) × 109/L,WBC levels of treatment group was (8.15 ± 1.84) × 109/L and that of and the control group was (6.57 ± 1.69 × 10)9/L,and the difference was statistically significant (P ＜ 0.05).After treatment,the ALT of the experimental group was 41.2 ± 22.4U · L-1 and that of and the control group was (60.1 ± 21.9) U · L-1,AST levels of the experimental group was 33.67 ± 18.46 U · L-1 and that of and the control group was (51.22 ± 16.95) U · L-1;The AST/ALT values were 0.78 ± 0.69,1.27 ± 0.73 in treatment group and in the control group,and the difference was statistically significant (P ＜ 0.05).Adverse drug reactions in treatment group was 40.63％ (13/32 cases),while it was 28.12％ (9/32 cases) in control group,thedifference was not statistically significant (P ＞ 0.05).Conclusion PEG-IFN-α-2a combined with riba virin could not only reduce HCV RNA positive rates,but also improve the serum AST and ALT levels in the treatment of hepatitis C virus-related cirrhosis underwent splenic embolization,which is safe.关键词
聚乙二醇干扰素α-2a/利巴韦林/丙型肝炎Key words
pegylated interferon α-2a/ribavirin/hepatitis C分类
医药卫生引用本文复制引用
杜合娟,蒋亦明,杨崎恩,陈仁芳,陆宇红,陈淼,周学士,曹弘..聚乙二醇干扰素α-2a注射液联合利巴韦林片治疗脾栓塞术后丙型病毒性肝炎肝硬化的临床研究[J].中国临床药理学杂志,2017,33(16):1523-1526,4.基金项目
南京医科大学科技发展基金资助项目(2013NJMU195) （2013NJMU195）
